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Abstract
A convergent and stereoselective synthesis of chiral cyclopentyl- and cyclohexylamine derivatives of nucleoside Q precursor
(PreQ0) has been accomplished. This synthetic route allows for an efficient preparation of 4-substituted analogues with interesting
three-dimensional character, including chiral cyclopentane-1,2-diol and -1,2,3-triol derivatives. This unusual substitution pattern
provides a useful starting point for the discovery of novel bioactive molecules.
Introduction
7-Deazapurine (pyrrolo[2,3-d]pyrimidine) nucleosides are
commonly found in nature playing a variety of roles such as
building blocks of nucleic acids and tRNA, metabolites or
antimetabolites [1]. Deazapurine ribonucleosides also show
interesting pharmacological profiles including antibacterial,
antiviral and anticancer properties [2-4]. Nucleoside Q
precursor (PreQ0) 1 is a common precursor in the biosynthesis
of queuosine (Q, 2) and archaeosine (G+, 3), two hyper-modi-
fied nucleosides present in the tRNA of prokaryote/eukaryote
and euryarchaeota, respectively [5,6]. In turn, the biosynthesis
of PreQ0 originates from guanosine 5-triphosphate (GTP, 4)
[7] (Figure 1) and involves four steps via a tetrahydropterine
intermediate.
The pyrrolo[2,3-d]pyrimidine core is a privileged scaffold for
the development of kinase inhibitors; an inspection of the medi-
cinal chemistry literature reveals >200 publications in the field.
Additionally, PreQ0 meets all the criteria dictated by the 2-0
rule of kinase-likeness proposed by Aronov et al. [8]. It is likely
that compounds derived from PreQ0 display kinase activity.
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Figure 1: Biosynthetic pathway leading to nucleosides queuosine and archaeosine.
Figure 3: Synthesis of PreQ0 and chloro-intermediate 9. Reagents and conditions: (a) Methyl formate, NaOMe, PhMe, 3 h, 0 °C; (b) 2,6-diamino-
pyrimidin-4(3H)-one, NaOAc, H2O, 17 h, 100 °C, 60% (over two steps); (c) PivCl, pyridine, 2 h, 85 °C, 64%; (d) POCl3, DMA, BnEt3NCl, MeCN, 1 h,
90 °C, 35%.
7-Deazapurine nucleoside chemistry has been the subject of
extensive study [1] and several syntheses of the PreQ0 base or
ribonucleoside [9-16] and queuosine [17] have been reported in
the literature. Despite this long-lasting interest, examples of
purine-based nucleosides containing a sugar or carbosugar
motif at the 4-position of the heterocyclic core (systematic
numbering) are scarce in the chemical literature and the
methods available generally lack experimental information,
making them unsatisfactory [18-25]. Inspired by the cyclopen-
tane-1,2,3-triol motif present in noraristeromycin 5 (Figure 2),
an IȚB kinase inhibitor with antiviral and anti-inflammatory
activity [26,27], we decided to investigate a synthetic route that
would allow for the incorporation of carbocyclic systems with
interesting three-dimensional character at the 4-position of
PreQ0 as part of our fragment-based kinase inhibitor library
generation programme.
Results and Discussion
Our retrosynthetic approach introduces the diversity point at a
late stage and takes advantage of the heterocyclic lactam present
Figure 2: Chemical structure of noraristeromycin.
in PreQ0 after activation and subsequent nucleophilic aromatic
substitution. This convergent synthesis allowed us to prepare
diverse chiral amine building blocks and react them with a
common halo-purine intermediate to obtain the desired final
products. The pyrrolo[2,3-d]pyrimidine core of PreQ0 was
furnished following a method described by Klepper et al. [13]
(Figure 3). The two step process started with the formylation of
chloroacetonitrile with methyl formate. The resulting volatile
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Figure 4: Synthesis of 15, a (1RS,2SR,3RS)-3-aminocyclopentane-1,2-diol derivative of PreQ0. Reagents and conditions: (a) NBS, (PhCO2)2, CCl4,
1 h, 90 °C; (b) NH(Bn)2, CCl4, 12 h, rt, 70% (over two steps); (c) OsO4, NMO, acetone/H2O, 4 h, rt, 72%, 96% ds; (d) BzCl, pyr, 24 h, 0 °C to rt, 84%;
(e) H2 (1 atm), Pd(OH)2, EtOH/EtOAc, 16 h, rt, 98%; (f) 9, Et3N, n-BuOH, 16 h, 130 °C; (g) KOH, n-BuOH/EtOH, 16 h, 80 °C, 42%.
and unstable chloroaldehyde 6 was used without further purifi-
cation. Cyclocondensation of 6 with 2,4-diamino-4-hydroxy-
pyrimidine afforded 1 regiospecifically with no detectable for-
mation of the undesired 6-substituted-furo[2,3-d]pyrimidine 7.
Direct chlorination of 1 in a moderate scale (1 g) using POCl3
proved to be very low yielding [28]. It remains unclear if this
was due to the poor solubility of PreQ0 or to the presence of
unprotected amino functionalities. In order to overcome this
issue, the exocyclic amine was protected [14] (Figure 3). The
resulting pivalamide 8 proved to be more soluble than 1 and the
subsequent halogenation step was accomplished in the presence
of a phase transfer catalyst, affording the desired chloro-inter-
mediate 9 in fair yield. In our hands, nucleophilic aromatic
substitution on 9 using amines of diverse nature usually
proceeds smoothly and allows for a clean pivalamide deprotec-
tion [29]. For this reason we decided to couple the chiral amines
of interest and remove protecting groups in a one-pot procedure.
First we investigated a more synthetically accessible
(1RS,2SR,3RS)-3-aminocyclopentane-1,2-diol core. Our
previous experience in coupling diols and triols at high
temperatures with chloro-intermediate 9 showed that more than
one unprotected alcohol functionality leads to complex reaction
mixtures and very low yields of isolated products [29], hence
we protected all hydroxy groups as esters. We chose the
benzoate protecting group to generate UVvisible intermedi-
ates and because its ease of cleavage under basic conditions
would converge with the final pivalamide deprotection step. We
adapted this protecting group strategy to Bonds synthetic route
since it was the most concise and diastereospecific available
[30] (Figure 4). The process started with a WohlZiegler allylic
bromination of cyclopentene. The volatile and unstable allylic
halide 10 was immediately reacted with excess N,N-dibenzyl-
amine and the resulting allylic amine 11 was obtained in good
yield over two steps. Next, we introduced the two hydroxy
groups trans- to the amine moiety using an Upjohn dihydroxy-
lation. Freshly-prepared aqueous OsO4 stock solutions were
required to obtain good yields in this step. The reaction
proceeded smoothly and the 1H NMR spectra of the crude reac-
tion mixture showed a 96:4 ratio of cis- to trans-isomers. After
column chromatography the isolated diol 12 showed a dia-
stereomeric purity of >99% by 1H NMR. The dibenzoate 13
was obtained in good yield following standard acylation condi-
tions [31]. Final removal of the two benzyl groups was accom-
plished in excellent yield using catalytic hydrogenation [30],
using EtOAc as a co-solvent to improve the substrate solubility.
Amine 14 was coupled with 9 and the pivalamide and benzoate
groups were cleaved in the one-pot procedure previously
described to afford 15, the (1RS,2SR,3RS)-3-aminocyclopen-
tane-1,2-diol derivative of PreQ0.
Adapting a protocol developed by Springthorpe et al. [32], we
then investigated a route to prepare the enantiopure
(1S,2R,3S,4R)-4-aminocyclopentane-1,2,3-triol analogue of
PreQ0 16 (Figure 5). The first step is a TsujiTrost allylation of
sodium di-tert-butyliminodicarboxylate. The reaction proceeded
with an overall retention of configuration as expected and the
1H NMR spectra of the crude reaction mixture only showed the
desired diastereomer 17. Several known catalytic systems were
tested [29]: Pd(PPh3)4/PPh3 in THF/DMF [33], Pd2(dba)3/
diphos in THF/DMF [34], Pd2(dba)3/dppf in THF [35]. The first
set of conditions proved to be the most successful, although
addition of DMF was required to improve the solubility of the
reactants. It is worth noting that this reaction proved to be
extremely sensitive to the presence of moisture and oxygen. The
bulky nature of the nucleophile used aided in the diastereose-
lectivity of the following syn-dihydroxylation. Using the
Upjohn conditions previously described we obtained the desired
Beilstein J. Org. Chem. 2014, 10, 13331338.
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Figure 5: Synthesis of 16, a (1S,2R,3S,4R)-4-aminocyclopentane-1,2,3-triol derivative of PreQ0. Reagents and conditions: (a) Pd(PPh3)4, PPh3, NaH,
NH(Boc)2, THF/DMF, 1 day, 50 °C, 42%; (b) OsO4, NMO, acetone/H2O, 1 day, rt, 83%; (c) BzCl, pyr, 17 h, 0 °C to rt, 74%; (d) 4 M HCl in 1,4-
dioxane, 16 h, 0 °C to rt, 76%; (e) 9, Et3N, n-BuOH, 16 h, 130 °C; (f) KOH, n-BuOH/EtOH, 16 h, 80 °C, 33%.
triol 18 in good yield and excellent diastereoselectivity (>99%
by 1H NMR after column chromatography) [30]. Tri-benzoate
19 was subsequently obtained in good yield using the standard
benzoylation conditions [31]. Final removal of the two BOC
protecting groups using 4 M HCl in 1,4-dioxane yielded amine
20 as the hydrochloride salt. Amine 20 was coupled with
chloro-intermediate 9 and the remaining four protecting groups
were cleaved in a one-pot procedure under basic conditions,
generating the desired triol 16.
To extend into hydrophobic chemical space around our PreQ0
analogues, we prepared two novel derivatives containing the
unusual 3-arylcyclohexylamine chiral motif present in 21 and
22. Zhou et al. had reported an asymmetric synthesis leading to
the cis-3-arylcyclohexanamines with reasonable diastereoselect-
ivity [36], but since initially we did not require an enantioselect-
ive synthesis and the Zhou method employed rather expensive
reagents, we investigated a simpler and cheaper route to access
both cis- and trans-isomers. We envisioned a stereoselective
synthesis that would potentially allow for the introduction of
diverse aryl groups at the 3-position of the cyclohexane ring
using commercially available arylboronic acids as building
blocks, and Pd catalysis to form the new CC bond, followed
by a highly diastereoselective ketone-to-amine conversion.
Others have reported on similar preparations of 3-phenylcyclo-
hexanamines, although with poor diastereomeric control
[37,38]. 1-Cyclohex-2-enone provided the two required syn-
thetic handles: a sp2 carbon for Pd chemistry and a ketone for
further derivatization into an amine group (Figure 6). The syn-
thesis of cis- and trans-3-arylcyclohexylamines 23 and 24
started with a Pd(II)-catalyzed Miyaura 1,4-conjugate addition
of phenylboronic acid to cyclohexenone [39]. The resulting
ketone 25 was reduced to the axial [40,41] and equatorial [40]
alcohols 26 and 27 with excellent diastereoselectivity thanks to
steric control of the hydride source. After column chromatog-
raphy both alcohols showed a diastereomeric purity of >99% by
1H NMR. Mitsunobu reaction on the secondary alcohols using
DEAD or DIAD did not provide the desired azides [42,43] nor
did a one-pot Appel reaction/nucleophilic substitution/
Staudinger reaction protocol involving a double inversion of
configuration [44]. Mesylation of 26 and 27 lead to intermedi-
ates 28 and 29 [45], which were subsequently reacted with
sodium azide inverting the stereochemistry as required [46]. A
final transfer hydrogenation of 30 and 31 yielded the desired
amines rapidly and with excellent yields [47]. Amines 23 and
24 were reacted with chloro-intermediate 9 and the pivalamide
groups were cleaved under basic hydrolysis conditions to yield
21 and 22.
Conclusion
In conclusion, a concise and stereoselective synthesis of novel
cyclopentyl and cyclohexyl analogues of PreQ0 has been devel-
oped to expand our fragment-based kinase library. This syn-
thetic protocol involves asymmetric syntheses of hydroxy-
protected (1RS,2SR,3RS)-3-aminocyclopentane-1,2-diol and
(1S,2R,3S,4R)-4-aminocyclopentane-1,2,3-triol or cis- and
trans-3-arylcyclohexylamines, which are in turn reacted with a
conveniently PreQ0-derived halo-intermediate and subse-
quently deprotected in a one-pot fashion. Pharmacological
assessment of these novel PreQ0 derivatives is currently
underway in a variety of kinase-inhibitory studies and will be
reported in due course.
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Figure 6: Synthesis of 21 and 22, 3-arylcyclohexylamine derivatives of PreQ0. Reagents and conditions: (a) PhB(OH)2, Pd(OAc)2, bpy, H2O/THF/
AcOH, 3 days, 60 °C, 98%; (b) K-Selectride, THF, 2 h, í90 °C; then KOH (aq), H2O2, 30 min, rt, 80%, 99% ds; (c) LiAlH4, Et2O, 1,5 h, 0 °C to rt; then
NaOH (aq), 30 min, rt, 76%, 97% ds (d) MsCl, Et3N, THF, 16 h, rt, (trans- 67%, cis- 64%); (d) NaN3, DMF, 2 days, 80 °C, (trans- 56%, cis- 67%); (f)
HCO2NH4, Pd/C, MeOH, 1.5 h, reflux, (trans- 92%, cis- 94%); (g) 9, Et3N, n-BuOH, 16 h, 130 °C; (h) KOH, n-BuOH/EtOH, 16 h, 80 °C, (trans- 38%,
cis- 50%).
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